Ep 81: IGNYTE trial (RP1 + nivo)

<p><strong>Summary</strong>The conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into clinical trial interpretation and treatment efficacy (and incorrect graphs).<strong>Takeaways</strong></p><ul><li>Clinical Trial Data</li><li>Treatment Efficacy</li></ul><p><br></p><p><strong>Chapters</strong></p><ul><li><a href="https://www.youtube.com/watch?v=29KTF6Rpvy8">00:00</a> Introduction to IGNYTE Study</li><li>14:04 Response Rate and Safety Profile</li><li>25:17 RNA-seq Analysis and Toxicity</li></ul>